Surgical Resection With Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients With Peritoneal Dissemination

Background: The prognosis On gastric cancel patients with peritoneal dissemination is very pool The purpose of this study was to evaluate the survival benefit from gastrectomy with hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancel patients with peritoneal dissemination Methods: From 1992 to 2002. 128 gastric cancer patients with peritoneal dissemination underwent surgery at the Department of Surgery, Ruijin Hospital. Shanghai, China The clinicopathological characteristics and survival wine computed between the resection and the non-resection groups. and between the resection alone and the resection with HIPEC groups Results: The 5-year survival rates were 5 5% for patients in the resection group and 0% for patients in the non-resection group (P < 0 001) Mutiny:mate analysis showed surgical resection was significantly associated with better prognosis in gastric cancer patients will: peritoneal dissemination In the patients who underwent resection, the survival difference between the resection alone and the resection with HIPEC groups was significant (P = 0 025). and HIPEC was an independent prognostic factor by multivariate analysis Conclusions: The HIPEC procedure was an independent prognostic factor after resection for patients with peritoneal dissemination Therefore. gastrectomy with HIPEC may be an option rot those patients The survival benefit of this strategy should be validated by large cohort prospective clinical trials J Surg Oncol 2010,102.361-365 (C) 2010 Wiley-Liss. Inc